Chugai Pharmaceutical (OTCMKTS:CHGCY) Hits New 52-Week High - Here's Why

Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY - Get Free Report) shares reached a new 52-week high during mid-day trading on Friday . The company traded as high as $30.91 and last traded at $29.81, with a volume of 99279 shares changing hands. The stock had previously closed at $28.98.

Chugai Pharmaceutical Trading Up 1.2 %

The company has a market cap of $99.32 billion, a P/E ratio of 39.20 and a beta of 0.76. The company has a 50-day simple moving average of $24.75 and a 200 day simple moving average of $23.23.

Chugai Pharmaceutical (OTCMKTS:CHGCY - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The company reported $0.19 EPS for the quarter. The company had revenue of $1.89 billion for the quarter. Chugai Pharmaceutical had a net margin of 33.07% and a return on equity of 21.53%. On average, equities analysts forecast that Chugai Pharmaceutical Co., Ltd. will post 0.74 EPS for the current fiscal year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.